22 results on '"Craig L. Slingluff"'
Search Results
2. Childhood cancer survivors face markedly worse overall survival after diagnosis with breast cancer, melanoma, or colorectal cancer
- Author
-
Shayna L. Showalter, Raj P Desai, William J. Kane, Craig L. Slingluff, Daniel E. Levin, Traci L. Hedrick, Mark A. Fleming, and Kevin T. Lynch
- Subjects
Adult ,Male ,Oncology ,medicine.medical_specialty ,Adolescent ,Colorectal cancer ,Breast Neoplasms ,Malignancy ,Article ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,Cancer Survivors ,Internal medicine ,Epidemiology ,medicine ,Humans ,Stage (cooking) ,Child ,Melanoma ,Aged ,Retrospective Studies ,business.industry ,fungi ,Hazard ratio ,Cancer ,General Medicine ,Prognosis ,medicine.disease ,Survival Rate ,Case-Control Studies ,030220 oncology & carcinogenesis ,Cohort ,Female ,030211 gastroenterology & hepatology ,Surgery ,Colorectal Neoplasms ,business ,Follow-Up Studies ,SEER Program - Abstract
BACKGROUND Childhood cancer survivors (CCS) are at elevated risk of secondary malignancies (SM). Enhanced screening for SM is recommended, but compliance is poor. We hypothesized that CCS with adult-onset SM (colorectal cancer [CRC], melanoma, or breast cancer [BC]) would present with more advanced disease and have decreased overall survival (OS). METHODS The Surveillance, Epidemiology, and End Results Program was queried for patients diagnosed with cancer at age less than or equal to 18 also diagnosed with adult-onset CRC, melanoma, or BC. A cohort without a history of prior malignancy was likewise identified. Tumor features and clinical outcomes were compared. RESULTS CCS with a SM (n = 224) were compared with patients without a childhood cancer history (n = 1,392,670). CCS were diagnosed younger (BC = 37.6 vs. 61.3, p
- Published
- 2021
3. TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10
- Author
-
Craig L. Slingluff, Yongde Bao, Donna H. Deacon, Walter C. Olson, Ileana S. Mauldin, and Ena Wang
- Subjects
Cancer Research ,Toll-like receptor ,Chemokine ,Tumor microenvironment ,Melanoma ,Biology ,medicine.disease ,TLR2 ,Immune system ,Oncology ,Immunology ,medicine ,biology.protein ,CXCL10 ,Interferon gamma ,medicine.drug - Abstract
Clinical approaches to treat advanced melanoma include immune therapies, whose benefits depend on tumor-reactive T-cell infiltration of metastases. However, most tumors lack significant immune infiltration prior to therapy. Selected chemokines promote T-cell migration into tumors; thus, agents that induce these chemokines in the tumor microenvironment (TME) may improve responses to systemic immune therapy. CXCL10 has been implicated as a critical chemokine supporting T-cell infiltration into the TME. Here, we show that toll-like receptor (TLR) agonists can induce chemokine production directly from melanoma cells when combined with IFNγ treatment. We find that TLR2 and TLR6 are widely expressed on human melanoma cells, and that TLR2/6 agonists (MALP-2 or FSL-1) synergize with interferon-gamma (IFNγ) to induce production of CXCL10 from melanoma cells. Furthermore, melanoma cells and immune cells from surgical specimens also respond to TLR2/6 agonists and IFNγ by upregulating CXCL10 production, compared to treatment with either agent alone. Collectively, these data identify a novel mechanism for inducing CXCL10 production directly from melanoma cells, with TLR2/6 agonists +IFNγ and raise the possibility that intratumoral administration of these agents may improve immune signatures in melanoma and have value in combination with other immune therapies, by supporting T-cell migration into melanoma metastases.
- Published
- 2015
4. Utility of sentinel lymph node biopsy for solitary dermal melanomas
- Author
-
Craig L. Slingluff, Puja Shah, Yinin Hu, and MA George J. Stukenborg PhD
- Subjects
medicine.medical_specialty ,medicine.diagnostic_test ,Cost effectiveness ,business.industry ,Wide local excision ,medicine.medical_treatment ,Melanoma ,Sentinel lymph node ,Cancer ,General Medicine ,Sentinel node ,medicine.disease ,Surgery ,Oncology ,Biopsy ,medicine ,business ,Survival rate - Abstract
Background and Objectives Solitary dermal melanoma (SDM) is melanoma confined to subcutaneous and/or dermal layers in the absence of a known primary cutaneous lesion. We hypothesized that sentinel node biopsy is an effective staging strategy for this rare disease. Methods A Markov decision model was constructed to represent two management strategies for SDM: wide local excision followed by observation, and wide local excision followed by sentinel node biopsy. Utilities, likelihood of positive sentinel node biopsy, and cancer progression rates during a five year time horizon were assigned based on institutional data and a review of existing literature. Estimated costs were derived using Medicare reimbursements. Results Excision followed by sentinel node biopsy provides greater utility, yielding 3.85 discounted quality-adjusted life years (dQALY) compared to 3.66 for excision alone. The incremental cost-effectiveness ratio for sentinel node biopsy is $19,102 per dQALY. Sensitivity analyzes demonstrated that observation is more cost-effective if greater than 23% of sentinel node biopsies are positive (16% reported), or if 5-year survival for observed patients is greater than 76% (69% reported). Conclusions Based on existing clinical evidence, sentinel node biopsy yields greater utility than excision alone and is cost-effective for patients presenting with solitary dermal melanoma. J. Surg. Oncol. 2015 111:800–807. © 2014 Wiley Periodicals, Inc.
- Published
- 2015
5. Total body photography for skin cancer screening
- Author
-
Anneke T. Schroen, Scott T. Acton, Gina R. Petroni, David Chen, Joshua M. Judge, Craig L. Slingluff, and Lynn T. Dengel
- Subjects
Male ,Pathology ,medicine.medical_specialty ,Skin Neoplasms ,Time Factors ,Attitude of Health Personnel ,Pilot Projects ,Image processing ,Dermatology ,Sensitivity and Specificity ,Article ,Image Processing, Computer-Assisted ,Photography ,Humans ,Medicine ,Melanoma ,Early Detection of Cancer ,Skin cancer screening ,business.industry ,Total body ,Image capture ,Visualization ,Patient Satisfaction ,Feasibility Studies ,Female ,Radiology ,Pigmented skin ,business ,Software ,Total body photography - Abstract
Background Total body photography may aid in melanoma screening but is not widely applied due to time and cost. We hypothesized that a near-simultaneous automated skin photo-acquisition system would be acceptable to patients and could rapidly obtain total body images that enable visualization of pigmented skin lesions. Methods From February to May 2009, a study of 20 volunteers was performed at the University of Virginia to test a prototype 16-camera imaging booth built by the research team and to guide development of special purpose software. For each participant, images were obtained before and after marking 10 lesions (five “easy” and five “difficult”), and images were evaluated to estimate visualization rates. Imaging logistical challenges were scored by the operator, and participant opinion was assessed by questionnaire. Results Average time for image capture was three minutes (range 2–5). All 55 “easy” lesions were visualized (sensitivity 100%, 90% CI 95–100%), and 54/55 “difficult” lesions were visualized (sensitivity 98%, 90% CI 92–100%). Operators and patients graded the imaging process favorably, with challenges identified regarding lighting and positioning. Conclusions Rapid-acquisition automated skin photography is feasible with a low-cost system, with excellent lesion visualization and participant acceptance. These data provide a basis for employing this method in clinical melanoma screening.
- Published
- 2014
6. T cells in the human metastatic melanoma microenvironment express site-specific homing receptors and retention integrins
- Author
-
Elise P. Salerno, Craig L. Slingluff, Walter C. Olson, Chantel McSkimming, and Sofia M. Shea
- Subjects
Cancer Research ,Tumor microenvironment ,Pathology ,medicine.medical_specialty ,biology ,Melanoma ,Integrin ,CXCR3 ,medicine.disease ,Chemokine receptor ,medicine.anatomical_structure ,Oncology ,biology.protein ,medicine ,Lymph node ,Homing (hematopoietic) ,Cancer immunology - Abstract
T-cell infiltration into the metastatic melanoma microenvironment (MME) correlates with improved patient survival. However, diffuse infiltration into tumor occurs in only 8% of melanoma metastases. Little is known about mechanisms governing T-cell infiltration into human melanoma metastases or about how those mechanisms may be altered therapeutically. We hypothesized that T cells in the MME would be enriched for chemokine receptors CCR4, CCR5, CXCR3 and homing receptors relevant to the tissue site. Viably cryopreserved single cell suspensions from nineteen melanoma metastases representing three metastatic sites (tumor-infiltrated lymph node, skin and small bowel) were evaluated by multiparameter flow cytometry and compared to benign lymph nodes and peripheral blood mononuclear cells from patients with Stage IIB-IV melanoma. T cells in the melanoma metastases contained large effector memory populations, high proportions of activated, moderately differentiated cells and few regulatory T cells. Site-specific homing was suggested in bowel, with high expression of CCR9. We neither encounter the anticipated enrichment of integrin α4β7 in bowel, cutaneous leukocyte antigen (CLA) in skin, nor integrin α4β1 or receptor CXCR3 in metastatic sites. Retention integrins αEβ7, α1β1 and α2β1 were significantly elevated in metastases. These data suggest limited tissue site-specific homing to human melanoma metastases, but a significant role for retention integrins in maintaining intratumoral T cells. Our findings also raise the possibility that T-cell homing, infiltration, and retention in melanoma metastases may be increased by increasing expression of ligands for CLA, α4β1 and CXCR3 on intratumoral endothelium.
- Published
- 2013
7. Amelanotic melanomas presenting as red skin lesions: a diagnostic challenge with potentially lethal consequences
- Author
-
Kira B. Mayo, Mark E. Smolkin, Craig L. Slingluff, Susannah E. McClain, Amber L. Shada, and James W. Patterson
- Subjects
medicine.medical_specialty ,Pathology ,medicine.diagnostic_test ,business.industry ,Melanoma ,Retrospective cohort study ,Dermatology ,Physician education ,medicine.disease ,Metastasis ,Medicine ,In patient ,Differential diagnosis ,business ,Skin lesion ,neoplasms ,Shave biopsy - Abstract
Objective To characterize epidemiologic and clinical features of red primary amelanotic melanomas, an atypical presentation of melanoma that is underemphasized in patient and physician education. Patients and methods Review of a prospectively collected melanoma database identified 46 patients with red amelanotic melanomas, whose clinical features were compared with 329 patients with pigmented melanomas from the same database and same timeframe from January 1964 to September 2005. Results Red amelanotic melanomas represented 3.9% of all melanomas recorded in our database and accounted for nearly 70% of amelanotic melanomas. Melanoma was included in the clinical differential diagnosis in 32% of red amelanotic melanomas vs. 94% of pigmented melanomas (P
- Published
- 2012
8. Surgical resection for bulky or recurrent axillary metastatic melanoma
- Author
-
Dustin M. Walters, Shannon N. Tierney, Amber L. Shada, and Craig L. Slingluff
- Subjects
Surgical resection ,medicine.medical_specialty ,Metastatic melanoma ,business.industry ,medicine.medical_treatment ,Melanoma ,Retrospective cohort study ,General Medicine ,medicine.disease ,Surgery ,Axilla ,medicine.anatomical_structure ,Oncology ,medicine ,Lymphadenectomy ,business ,Prospective cohort study ,Survival rate - Abstract
Introduction Metastatic melanoma has few FDA approved treatments, and aggressive surgical resection has to be considered for management of bulky axillary metastases. We hypothesized that axillary resection in this setting is well tolerated and improves symptoms in the majority of patients.
- Published
- 2011
9. VEGFR-2 expression in human melanoma: Revised assessment
- Author
-
James W. Patterson, Cheryl F. Murphy, Craig L. Slingluff, Kerrington R. Molhoek, J K Rasamny, Gulsun Erdag, David L. Brautigan, and Donna H. Deacon
- Subjects
Cancer Research ,Immunoblotting ,Biology ,Antibodies ,Article ,chemistry.chemical_compound ,Cell Line, Tumor ,medicine ,Humans ,Neoplasm Metastasis ,Autocrine signalling ,Melanoma ,integumentary system ,Transfection ,medicine.disease ,Immunohistochemistry ,Vascular Endothelial Growth Factor Receptor-2 ,Molecular biology ,Vascular endothelial growth factor ,Oncology ,chemistry ,Tissue Array Analysis ,Cell culture ,embryonic structures ,cardiovascular system ,biology.protein ,Antibody ,Immunostaining - Abstract
Vascular endothelial growth factor (VEGF) is an angiogenic factor that also functions as an autocrine growth factor for VEGF receptor (VEGFR)-2(+) melanomas. In multiple studies, VEGFR-2 was detected by immunostaining in 78-89% of human melanoma cells, suggesting that most patients with melanoma would benefit from anti-VEGF therapy. Here, we evaluated 167 human melanoma specimens in a tissue microarray to verify the presence of VEGFR-2, but found disparities in staining with commercial antibodies A-3 and 55B11. Antibody A-3 stained melanoma cells in 79% of specimens, consistent with published results; however, we noted extensive nonspecific staining of other cells such as smooth muscle and histiocytes. In contrast, antibody 55B11 stained melanoma cells in only 7% (95% confidence interval: 3.3-11.5) of specimens. As an internal positive control for VEGFR-2 detection, vascular endothelial cells were stained with antibody 55B11 in all specimens. We compared VEGFR-2(+) and VEGFR-2(-) melanoma cell lines by immunoblotting and immunohistochemistry after small interfering RNA (siRNA) knockdown and transient overexpression of VEGFR-2 to validate antibody specificity. Immunoblotting revealed that A-3 primarily cross-reacted with several proteins in both cell lines and these were unaffected by siRNA knockdown of VEGFR-2. In contrast, 55B11 staining of VEGFR-2(+) cells was mostly eliminated by siRNA knockdown of VEGFR-2 and increased in VEGFR-2(-) melanoma cell lines following transfection to express ectopic VEGFR-2. Our results show that relatively few melanoma cells (10%) express detectable levels of VEGFR-2, and therefore, the majority of patients with melanoma are unlikely to benefit from antiproliferative effects of anti-VEGF therapy.
- Published
- 2011
10. Subclassification of desmoplastic melanoma: pure and mixed variants have significantly different capacities for lymph node metastasis
- Author
-
Susannah E. McClain, James W. Patterson, Nayak L. Polissar, Evan George, and Craig L. Slingluff
- Subjects
Adult ,Male ,medicine.medical_specialty ,Pathology ,Skin Neoplasms ,Histology ,Mitotic index ,Dermatology ,Pathology and Forensic Medicine ,Biopsy ,medicine ,Humans ,Melanoma ,Lymph node ,Aged ,Neoplasm Staging ,Aged, 80 and over ,Desmoplastic melanoma ,medicine.diagnostic_test ,business.industry ,Incidence (epidemiology) ,Cancer ,Anatomical pathology ,Middle Aged ,medicine.disease ,Immunohistochemistry ,medicine.anatomical_structure ,Lymphatic Metastasis ,Female ,business - Abstract
Background: There is disagreement about the behavior and optimal management of desmoplastic melanoma (DM), particularly regarding the incidence of lymph node (LN) involvement. Recently, investigators have noted the frequently heterogenous histologic composition of DM and have found significant differences between pure desmoplastic melanoma (PDM) (≥90% comprised of histologically typical DM) and mixed desmoplastic melanoma (MDM) [≥10% DM and >10% conventional melanoma (CM)]. Method: We reviewed 87 cases of DM comparing the histologic and clinical features of PDM (n = 44) to MDM (n = 43). Results: At surgical staging, there were LN metastases in 5 of 23 (22%) MDM patients, whereas all 17 PDM patients had negative LN biopsies (0%) (p = 0.04). PDM was less often clinically pigmented (36% vs. 67%) and had a lower mean mitotic index (1.3 vs. 3.0). Conclusions: There are differences between PDM and MDM, the most important of which is the incidence of LN involvement. Our findings support the clinical utility of classifying DM into pure and mixed subtypes because the negligible rate of nodal involvement in PDM does not support the routine performance of sentinel LN biopsy in this subgroup of melanoma patients. In contrast, the incidence of LN involvement in MDM is comparable to that of CM.
- Published
- 2009
11. Extensive neurocristic hamartoma with skeletal muscle involvement
- Author
-
Chadrick E. Denlinger, James W. Patterson, Martin C. Mihm, and Craig L. Slingluff
- Subjects
Male ,medicine.medical_specialty ,Pathology ,Cell type ,Histology ,Biopsy ,Hamartoma ,Subcutaneous Fat ,Physical examination ,Dermatology ,Malignancy ,Skin Diseases ,Pathology and Forensic Medicine ,medicine ,Humans ,Muscle, Skeletal ,Aged ,medicine.diagnostic_test ,business.industry ,Melanoma ,Anatomical pathology ,medicine.disease ,Pleomorphism (cytology) ,Positron emission tomography ,Positron-Emission Tomography ,business - Abstract
Neurocristic hamartomas (NCH) are rare pigmented skin lesions based in the deep subcutaneous tissues that may be either congenital or acquired. The clinical importance of these lesions is the potential for misdiagnosis and the development of malignant melanomas over a poorly described time course. Histological pleomorphism precludes meaningful random biopsies as a means of cancer surveillance. We present the case of an extensive NCH in a 67-year-old man, with a reported duration of greater than 50 years and no current clinical or histological indication of malignancy. Incisional biopsies of nodular areas showed bland-appearing pigmented cells that extended into subcutaneous adipose tissue and skeletal muscle. The specimens contained numerous clusters of differing configurations and cell types. Positron emission tomography (PET) scanning was used as an adjunct to physical examination in follow up. A PET-avid mass was detected but proved to be a banal nodular melanocytic proliferation within the NCH. In conclusion, NCH may be characterized by extensive deep tissue involvement in the absence of overt malignancy. The possible development of malignant melanoma in such lesions warrants close surveillance.
- Published
- 2007
12. Problems in the interpretation of apparent ‘radial growth phase’ malignant melanomas that metastasize
- Author
-
Liana Abramova, James W. Patterson, and Craig L. Slingluff
- Subjects
Pathology ,medicine.medical_specialty ,Histology ,business.industry ,Melanoma ,Radial Growth Phase ,Dermatology ,Melanocytic nevus ,Compound nevus ,medicine.disease ,Pathology and Forensic Medicine ,Metastasis ,Lesion ,Vertical growth ,medicine ,Vertical Growth Phase ,medicine.symptom ,business - Abstract
Background: The delineation of radial and vertical growth phases in primary cutaneous malignant melanomas has contributed to our understanding of melanoma progression and has enhanced the ability of pathologists to provide clinicians with meaningful prognostic information. Vertical growth phase (VGP) lesions have the potential to metastasize, but radial growth phase (RGP) melanomas are believed to lack competence for metastasis. Methods: We have identified three cases in which metastasis occurred in association with lesions initially interpreted as RGP melanomas. To determine whether these cases truly represented exceptional metastasizing RGP melanomas or VGP lesions incorrectly identified as RGP lesions, careful microscopic re-review of these cases was performed. Results: In one case, additional microscopic sectioning revealed a focus of vertical growth that was not evident on the original sections. In the other two cases, only radial growth was found. In one of these cases there was melanoma in situ with regressive changes, but no evidence for invasive melanoma. In the other, a RGP lesion was associated with an adjacent compound nevus with periadnexal involvement. Conclusions: These cases suggest that, while true RGP melanomas have an excellent prognosis, caution must be exercised in defining a lesion as having no metastatic potential when multiple sections of the primary lesion are unavailable, when the lesion is accompanied by regressive changes, or when there is an associated melanocytic nevus. It is possible that strictly defined RGP melanomas may metastasize in very rare cases. Our observations also suggest that metastatic potential is a function of numerous factors, and may not be evaluable on morphological grounds alone.
- Published
- 2002
13. Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients
- Author
-
William W. Grosh, Shannon Eastham, Patrice Y. Neese, Holly Galavotti, Donna L. Barnd, James W. Patterson, Craig L. Slingluff, David Teates, Victor H. Engelhard, Galina V. Yamshchikov, Donna H. Deacon, and Gina R. Petroni
- Subjects
Cancer Research ,business.industry ,medicine.medical_treatment ,Immunogenicity ,Melanoma ,Tyrosinase Peptide ,chemical and pharmacologic phenomena ,Immunotherapy ,medicine.disease ,CTL ,Immune system ,Oncology ,Immunology ,Peptide vaccine ,Medicine ,business ,Adjuvant - Abstract
Many peptide epitopes for cytotoxic T lymphocytes (CTLs) have been identified from melanocytic differentiation proteins. Vaccine trials with these peptides have been limited mostly to those associated with HLA-A2, and immune responses have been detected inconsistently. Cases of clinical regression have been observed after peptide vaccination in some trials, but melanoma regressions have not correlated well with T-cell responses measured in peripheral blood lymphocytes (PBLs). We vaccinated stage IV melanoma patients with a mixture of gp100 and tyrosinase peptides restricted by HLA-A1 (DAEKSDICTDEY), HLA-A2 (YLEPGPVTA and YMDGTMSQV) and HLA-A3 (ALLAVGATK) in an emulsion with GM-CSF and Montanide ISA-51 adjuvant. CTL responses were assessed in PBLs and in a lymph node draining a vaccine site (sentinel immunized node, SIN). We found CTL responses to vaccinating peptides in the SIN in 5/5 patients (100%). Equivalent assays detected peptide-reactive CTLs in PBLs of 2 of these 5 patients (40%). CTLs expanded from the SIN lysed melanoma cells naturally expressing tyrosinase or gp100. We demonstrated immunogenicity for peptides restricted by HLA-A1 and -A3 and for 1 HLA-A2 restricted peptide, YMDGTMSQV. Immune monitoring of clinical trials by evaluation of PBLs alone may under-estimate immunogenicity; evaluation of SIN provides a new and sensitive approach for defining responses to tumor vaccines and correlating these responses with clinical outcomes. This combination of an immunogenic vaccine strategy with a sensitive analysis of CTL responses demonstrates the potential for inducing and detecting anti-tumor immune responses in the majority of melanoma patients.
- Published
- 2001
14. Short length of stay and rapid recovery to normal function after surgery for metastatic melanoma to abdominal and retroperitoneal viscera
- Author
-
Craig L. Slingluff and Lynn T. Dengel
- Subjects
Poor prognosis ,medicine.medical_specialty ,Metastatic melanoma ,business.industry ,Melanoma ,General Medicine ,Perioperative ,Short length ,medicine.disease ,Retroperitoneal Neoplasm ,Metastasis ,Surgery ,medicine.anatomical_structure ,Oncology ,medicine ,Abdomen ,business - Abstract
Background Metastatic melanoma to abdominal and retroperitoneal viscera carries a poor prognosis possibly resulting in reluctance to offer surgical management. There is value in defining the morbidity of such surgery. Methods Review of a prospectively maintained database identified patients with metastatic melanoma to abdominal or retroperitoneal viscera who underwent surgery from 9/99 to 8/06. Results Nineteen patients underwent surgery for metastasis to abdominal or retroperitoneal viscera detected by clinical symptoms (80%), or imaging (20%). The median length of stay was 7 days. There was no perioperative mortality. Surgical complications occurred in four patients. At initial follow-up, 13 patients (68%) had returned to baseline function, 7 of which reported improvement. Four patients (21%) had minimal symptoms, and only two patients (11%) had significantly limited function. Median follow-up was 35 months, at which time 9 of the 19 patients (47%) were still alive, with 3- and 5-year Kaplan–Meier survival estimates of 53% (SE 12) and 45% (SE 12), respectively, and 2 of the 19 patients are alive at over 8 years since surgery. Conclusion In selected cases, surgery may have both palliative benefit and curative potential for patients with visceral metastases of melanoma. Surgical management of such patients should be encouraged in appropriate clinical settings. J. Surg. Oncol. 2009;100:481–483. © 2009 Wiley-Liss, Inc.
- Published
- 2009
15. Terminal modifications inhibit proteolytic degradation of an immunogenic mart-127-35 peptide: Implications for peptide vaccines
- Author
-
Lee W. Thompson, Galina V. Yamshchikov, Craig L. Slingluff, Holly Galavotti, Vladimir V. Kalashnikov, Laurence H. Brinckerhoff, Victor H. Engelhard, and Richard A. Pierce
- Subjects
chemistry.chemical_classification ,Cancer Research ,medicine.diagnostic_test ,Chemistry ,Immunogenicity ,Proteolysis ,Peptide ,In vitro ,Epitope ,CTL ,Oncology ,Biochemistry ,In vivo ,PEGylation ,medicine - Abstract
Peptide epitopes for tumor-reactive cytotoxic T-lymphocytes (CTL) have been identified on human cancers and are being used in tumor vaccine trials. However, the pharmacokinetics and pharmacodynamics of such peptides have been inadequately studied. It is predicted that immunogenic tumor peptides would have short half-lives in vivo. The goal of the present work was to evaluate the stability of the immunogenic peptide MART-1(27-35) in fresh normal human plasma (NHP) and to identify modifications that convey protection against enzymatic destruction without loss of immunogenicity. We evaluated the stability of the MART-1(27-35) peptide (AAGIGILTV) and modified forms of that peptide for stability and immune recognition in an in vitro model. The peptides were incubated in plasma for varied time intervals and evaluated for their ability to reconstitute the epitope for MART-1(27-35)-reactive CTL. Loss of CTL reactivity signaled loss of immunoreactive peptide. When 1 microM MART-1(27-35) peptide was incubated in plasma prior to pulsing on target cells, CTL reactivity was lost within 3 hr, and the calculated half-life of this peptide was 22 sec. This degradation was mediated by peptidases. The stability of MART-1(27-35) was markedly prolonged by C-terminal amidation and/or N-terminal acetylation (peptide capping), or by polyethylene-glycol modification (PEGylation) of the C-terminus. These modified peptides were recognized by CTL. The MART-1(27-35) peptide is very unstable in plasma. It is probable that it and other immunogenic peptides will be similarly unstable in vivo. Immunogenicity of these peptides might be enhanced by creating modifications that enhance stability.
- Published
- 1999
16. Mass‐spectrometric evaluation of HLA‐A*0201‐associated peptides identifies dominant naturally processed forms of CTL epitopes from MART‐1 and gp100
- Author
-
Jeffrey Shabanowitz, Ronald C. Hendrickson, Nancy L. Harthun, Jennifer A. Caldwell, Pamela H. Gulden, Victor H. Engelhard, Jonathan C.A. Skipper, Donald F. Hunt, and Craig L. Slingluff
- Subjects
chemistry.chemical_classification ,Cancer Research ,Cellular immunity ,Melanoma ,Cancer ,Peptide ,Biology ,medicine.disease ,Epitope ,Immune system ,Oncology ,chemistry ,In vivo ,Immunology ,Cancer research ,medicine ,Cytotoxic T cell - Abstract
Melanoma-reactive human cytotoxic T lymphocytes (CTLs) mediate tumor regression in vivo through specific recognition of MHC-associated peptide epitopes, many of which are encoded by the melanocytic tissue differentiation proteins gp100/Pmel17 and MART-1/Melan-A. Vaccines using these peptides may induce protective or therapeutic immunity against melanoma. Rational design of such approaches is aided by a clear understanding of the identity of these antigenic peptides; however, most CTL epitopes described to date were identified indirectly. Especially where these peptides may be used in human clinical trials for the treatment or prevention of cancer, there is substantial need for direct evaluation of HLA-A*0201-associated peptides from MART-1 and gp100 that are naturally processed and presented. To that end, we have isolated peptides directly from HLA-A*0201 molecules of human melanoma cells and have determined that naturally processed epitopes for HLA-A*0201-restricted, melanoma-reactive CTLs include the nonamers MART-127–35 (AAGIGILTV), gp100154–162 (KTWGQYWQV), gp100209–217 (ITDQVPFSV) and gp100280–288 (YLEPGPVTA) and the decamer gp100476–485 (VLYRYGSFSV). Among these, the one that appears to be most abundant at the cell surface is gp100154–162 (KTWGQYWQV). The others are among the less abundant peptides. HLA-A*0201-restricted CTLs from one melanoma patient who has survived metastatic disease recognized MART-127–35 (AAGIGILTV), gp100280–288 (YLEPGPVTA) and gp100154–162 (KTWGQYWQV) and were cross-reactive on longer peptides that contained these nonamer sequences. These peptides, identified by both an indirect genetic approach and by a direct peptide approach, can be used for tumor vaccine strategies with confidence that they are identical to the naturally processed peptide epitopes presented at the surface of melanoma cells in association with HLA-A*0201 molecules. Int. J. Cancer 82:669–677, 1999. © 1999 Wiley-Liss, Inc.
- Published
- 1999
17. Tumor antigens and tumor vaccines: Peptides as immunogens
- Author
-
Craig L. Slingluff
- Subjects
Tumor-infiltrating lymphocytes ,medicine.medical_treatment ,Antigen presentation ,Dendritic cell ,Immunotherapy ,Biology ,CTL ,Oncology ,Antigen ,Immunology ,medicine ,Cytotoxic T cell ,Surgery ,Pan-T antigens - Abstract
Tumor antigens recognized by human cytotoxic T lymphocytes (CTL) have been identified for multiple types of solid tumors. These include both shared and unique antigens. Unique antigens are those expressed uniquely by one patient's tumor, and shared antigens are those present on tumor cells from many different patients. Many of the shared antigens are derived from tissue-specific differentiation antigens, oncogenes, or a set of antigens expressed only in tumors or in testis. In addition to advances in understanding tumor antigens that stimulate CTL and T-helper cell responses, there have been advances in understanding immunity in general, including the characterization of cytokines, the recognition of the dendritic cell as an optimal antigen-presenting cell (APC), and the characterization of costimulatory molecules as critical components of antigen presentation. Together, these developments have breathed new life into tumor immunology, and they promise to lead to a new generation of peptide- and cell-based tumor vaccines.
- Published
- 1996
18. Malignant Melanoma and the Prognostic Implications of Pregnancy, Oral Contraceptives, and Exogenous Hormones
- Author
-
Craig L. Slingluff and Douglas Reintgen
- Subjects
Oncology ,Surgery - Published
- 1993
19. The annual risk of melanoma progression. Implications for the concept of cure
- Author
-
Hilliard F. Seigler, Craig L. Slingluff, Wilma E. Stanley, and Richard K. Dodge
- Subjects
Cancer Research ,medicine.medical_specialty ,Pediatrics ,business.industry ,Melanoma ,Clinical course ,Cancer ,Disease ,medicine.disease ,Surgery ,Oncology ,Late Recurrence ,Recurrent disease ,Risk of mortality ,Medicine ,In patient ,business - Abstract
Background. Melanoma may remain clinically dormant for years, and patients may have distant metastatic disease decades after the initial diagnosis is made. Because of this potential for late recurrence, the concept of “cure” for melanoma is not particularly meaningful. Methods. To understand better the risks of future disease as a function of time elapsed after diagnosis, the clinical course of melanoma was reviewed in 5838 patients. Using conditional probability methods, the risk of recurrent disease and the risk of death were determined for 1-year and 5-year intervals during the first 15 years of follow-up. Results. The estimated 5-year risk of recurrence declined from 44% at the time of diagnosis to 21% after 6 years. The 5-year risk of mortality decreased from 26% after 1 year to 16% after 9 years. Among patients with recurrent or metastatic disease, the annual risk of mortality was approximately 20% per year for 3 years; thereafter, the risk declined markedly. Among patients with thick primary lesions, the greatest risk was during the first few years after diagnosis, but in patients with thin lesions, the risk was distributed evenly over 15 years and did not decrease with time. Conclusions. Conditional probability methods permit estimation of future risks to address questions frequently asked by patients with cancer who want to know when they can be considered cured of cancer or when the risk of recurrent disease has decreased. These data on the future risk of recurrent disease and mortality can give a patient meaningful information on which to base life decisions. Cancer 1992 70:1917-1927.
- Published
- 1992
20. Acral with melanoma: A review of 185 patients identification of prognostic variables
- Author
-
Robin T. Vollmer, Hilliard F. Seigler, and Craig L. Slingluff
- Subjects
Prognostic variable ,medicine.medical_specialty ,Proportional hazards model ,business.industry ,medicine.medical_treatment ,Melanoma ,Incidence (epidemiology) ,Histology ,General Medicine ,Active immunotherapy ,medicine.disease ,Dermatology ,Oncology ,Amputation ,medicine ,Surgery ,business ,Survival rate - Abstract
One hundred eight-five patients with acral melanoma treated since 1972 were reviewed. These included 53 subungual lesions, 123 plantar lesions, and 9 palmar lesions. Eighty percent presented with stage I disease. Mean age was 57 years. Males outnumbered females 1.1:1. Seventeen percent (17%) were blacks. Actuarial 10-year survival was 58% for stage I patients and 35% for stage II patients. Univariate Cox regression analyses identified 5 prognostic variables affecting survival: stage at diagnosis (P less than 0.001), race (P less than 0.001), ulceration (P = 0.012), Clark's level (P = 0.014), and thickness of the primary lesion (P = 0.013). Factors unrelated to survival included sex of the patient, site (volar vs. subungual), histology, and treatment with amputation. Multivariate analysis for patients with stage I lesions identified race (P = 0.001) and ulceration (P = 0.018) as significant variables, with thickness approaching significance (P = 0.094). In an additional series of 71 patients with melanomas arising from extremity sites near the junction of glabrous and non-glabrous skin, survival was significantly poorer for those arising from glabrous skin (P = 0.024), and reflects a higher incidence of metastatic disease at diagnosis. Specific active immunotherapy was the principal adjuvant used for these patients, and survival was comparable to that reported with regional perfusion therapy. Acral melanoma a) has a strong racial predilection, b) carries a grave prognosis, and c) arises from glabrous skin. It is a clinical entity distinct from other extremity melanomas. Surgical management with either wide excision or amputation is appropriate for the primary lesion.
- Published
- 1990
21. Inhibition of the growth of human melanoma xenografts in nude mice by human tumor-specific cytotoxic T-cells
- Author
-
Craig L. Slingluff, Carol E. Vervaert, Nancy J. Crowley, Hilliard F. Seigler, and Timothy L. Darrow
- Subjects
Male ,medicine.medical_treatment ,Transplantation, Heterologous ,Fluorescent Antibody Technique ,Mice, Nude ,Heterologous ,Mice ,In vivo ,HLA-A2 Antigen ,medicine ,Animals ,Humans ,Cytotoxic T cell ,Melanoma ,Mice, Inbred BALB C ,business.industry ,General Medicine ,Immunotherapy ,medicine.disease ,In vitro ,Transplantation ,Oncology ,Immunology ,Cancer research ,Surgery ,Human melanoma ,business ,Neoplasm Transplantation ,T-Lymphocytes, Cytotoxic - Abstract
Melanoma-specific T-cells (CTLs) are specifically cytotoxic for autologous tumor, when assayed in vitro. To examine their effectiveness in vivo, we tested the ability of these human T-cells to inhibit growth of human melanoma xenografts by using a Winn assay. Nude mice receiving specific CTLs (n = 10) demonstrated a dramatic inhibition of tumor growth. All treated mice were tumor-free at day 50 and nine remained tumor-free at day 65, vs. control mice (n = 10) with average tumor volumes of 321 mm3 and 808 mm3, respectively. To control for the possibility that a non-specific response to the human T-cells could inhibit tumor growth, an additional group received allospecific CTLs. There was no inhibition of tumor growth in this group (n = 8), with the average tumor volume of 2,768 mm3 at day 40 vs. 1,882 mm3 in the control group (n = 10). We conclude that these tumor-specific CTLs can inhibit tumor growth in vivo and may prove useful in the adoptive immunotherapy of melanoma.
- Published
- 1990
22. Autologous lymph node cell-derived tumor-specific cytotoxic t-cells for use in adoptive immunotherapy of human melanoma
- Author
-
Timothy L. Darrow, Hilliard F. Seigler, and Craig L. Slingluff
- Subjects
Cancer Research ,Lymphokine-activated killer cell ,business.industry ,Melanoma ,medicine.medical_treatment ,Immunotherapy ,medicine.disease ,Natural killer cell ,medicine.anatomical_structure ,Oncology ,Cell culture ,Immunology ,Cancer research ,Medicine ,Cytotoxic T cell ,business ,Lymph node ,CD8 - Abstract
The in vitro development of tumor-specific cytotoxic T-cells from draining and tumor-involved lymph nodes obtained from melanoma patients were examined. Fresh draining or tumor-involved lymph node cells (LNC) demonstrate no significant cytotoxic activity against a variety of tumor targets including autologous melanoma. Natural killer cell (NK) activity is very low or absent in all of these specimens. Culture of the cells with irradiated autologous tumor and expansion in recombinant interleukin 2 (rIL-2) results in strong cytotoxicity for autologous tumor cells. The cultured cells are T-cells of mixed CD4 and CD8 phenotypes. Following restimulation with autologous tumor, these lines are capable of becoming specifically cytotoxic for autologous tumor as tested in direct killing and in cold target inhibition studies. The LNC yield from fresh specimens ranges from 1 X 10(7) to more than 1 X 10(9) cells averaging 5 X 10(8) cells. After the cells are cultured, we can achieve up to a 60-fold or more increase in cell numbers, that demonstrate strong cytotoxicity for melanomas. The potential for adoptive immunotherapy using such specifically sensitized cytotoxic T-cells of mixed phenotypes is discussed.
- Published
- 1988
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.